At Dennis Partners, we know regulatory recruiting. We are committed to creating and maintaining partnerships with our clients while upholding the highest standards of professionalism and ethics. Our team interacts within the marketplace on a daily basis, giving us the ability to locate, screen, and recommend exceptional individuals to your firm. We know how to identify the top performers. Our strength is partnering with you and your business to develop a solution and meet demands for growth while improving efficiency. Let our advanced expertise find the top professionals in the industry to provide a competitive edge to your company.
We have your specialization covered
Contract-to-hire evaluation process
We're on your side
Complete back office support
Our process is cost-effective
Dennis Partner’s focus on only regulatory affairs searches gives them a very good sense of the market, the available talent, and who matches the role. They worked with us diligently to find the right candidate and we ended up making an exceptional hire.
We take the time to evaluate your needs beyond a job description
We identify top talent from our research and competitive analysis
We analyze the talent to match candidates on a deeper level
We go beyond the hire by offering extensive post placement services
Does your company have immediate top-tier talent needs?
Meet Our Team
I am posting this week’s regulatory update a day early since our office will be closed tomorrow for the holiday weekend. Only one new molecular entity was approved this week, along with a couple of new indication approvals. The FDA approved Kevzara (sarilumab), a treatment of rheumatoid arthritis which was co-developed by Sanofi and Regeneron. […]
Regulatory Roundup: Top News Stories – Week Ending May 19, 2017 There have been a lot of regulatory announcements so far this week. Here are the top ten stories for regulatory professionals to follow: Scott Gottlieb, the newly sworn-in commissioner of the FDA indicated that he plans to put rising drug prices front and center[…]
It can be an exciting and anxious time when considering relocating for your next Strategic Career Move. When having these conversations with candidates I always counsel them to consider the five tips below to make sure they are making an informed decision. 1 – Location: Cost of living can differ significantly by geographic location. We have[…]
There has been a lot of big news in the industry this week and here are some of the key regulatory highlights: The U.S. Senate confirmed Dr. Scott Gottlieb as the next commissioner of the FDA. Gottlieb, 44, served as an FDA deputy commissioner during the George W. Bush administration. He has also worked as[…]
There has been a lot of big news in the industry this week and here are some of the key regulatory highlights: The U.S. Senate confirmed Dr. Scott Gottlieb as the next commissioner of the FDA. Gottlieb, 44, served as an FDA deputy commissioner during the George W. Bush administration. He has also worked as a[…]
The U.S. job market bounced back in April, adding 211,000 nonfarm payroll jobs during the month, according to data released today by the U.S. Bureau of Labor Statistics. The gains exceeded Bloomberg economists’ prediction of 190,000 jobs added, and followed a weaker-than-expected March that saw 79,000 jobs added, revised down from the previously reported 98,000[…]
In today’s highly competitive job market, businesses can’t afford to take a lackluster approach to recruitment and hiring. Not only can a bad hire lead to costly turnover, but it can also negatively impact the organizational performance of a business and, therefore, its bottom line. According to the Society for Human Resources Management, the cost[…]
Have you noticed how technology’s claim is that it will improve the quality of life, but it seems more like technology is taking over our lives? It has created a sense of constant accessibility, which leads to higher expectations in terms of finishing tasks and doing business. It’s been my impression that it’s considered acceptable[…]
This has been another exciting week with a flurry of regulatory activity in pharma and biotech. The FDA approved Radius Health’s drug TYMLOS to treat osteoporosis in postmenopausal women at high risk of fracture or those who have failed other therapies. However, this included a “black box” warning that the treatment had increased the[…]
This past week has been busy with lots of big announcements in the industry. Here are some of the top stories which are creating buzz in the regulatory world: The FDA approved Takeda/Ariad’s ALUNBRIG for the treatment of non-small cell lung cancer. This is great news for Takeda who recently completed their purchase of Ariad. ALUNBRIG is an orphan[…]